<DOC>
	<DOC>NCT02420132</DOC>
	<brief_summary>Study to Evaluate Home Vision Testing in Patients Receiving Ranibizumab</brief_summary>
	<brief_title>Study to Evaluate Home Vision Testing in Patients Receiving Ranibizumab</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Diabetic Macular Edema (DME) or active neovascular agerelated Macular Degeneration (nAMD) in at least one eye Current treatment with intravitreal LucentisÂ® therapy, with evaluations planned every 4 to 8 weeks Best corrected visual acuity (Snellen assessed by glasses and/or contact lens) of 20/100 or better in the study eye, with potential for vision recovery with standardofcare treatment Age &gt;= 18 years Access to an approved mobile device with a data plan or WiFi internet access Any other eye condition causing eye disease that limits vision and cannot be corrected, other than Diabetic Macular Edema (DME) or neovascular agerelated Macular Degeneration (nAMD). Dementia or other neurologic or psychological limitation that would prevent the patient from performing regular selftesting of visual function.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>